Childhood obesity: rapid weight gain in early childhood and subsequent cardiometabolic risk

Osamu Arisaka1,2, Go Ichikawa1,2, Satomi Koyama2

  • 1Department of Pediatrics, Nasu Red Cross Hospital, Tochigi, Japan.

Insights

Rapid weight gain in infancy and early childhood can increase health risks. Emerging evidence suggests toddlers showing increased body mass index (BMI) before age 3 are prone to later cardiometabolic risk.

Area of Science:

  • Pediatrics
  • Public Health
  • Metabolic Health

Background:

  • Dynamic body weight changes are key health risk indicators.
  • Rapid infant and early childhood weight gain is linked to later obesity, type 2 diabetes, and cardiovascular diseases.
  • Consensus is lacking on which specific weight gain period poses the greatest future risk.

Purpose of the Study:

  • To review evidence on early rapid growth and future obesity and cardiometabolic risk.
  • To focus on the distinct significance of rapid weight gain during infancy versus early childhood.
  • To identify critical periods of growth influencing long-term health outcomes.

Main Methods:

  • Systematic review of recent observational studies.
  • Analysis of data focusing on weight gain trajectories in infancy (before 1 year) and early childhood (before 3 years).
  • Evaluation of associations between early growth patterns and later development of obesity and cardiometabolic risk factors.

Main Results:

  • Childhood growth before 1 year warrants attention for potential links to future obesity.
  • Emerging evidence strongly links increased BMI in toddlers before 3 years to later cardiometabolic risk.
  • This period of BMI increase in toddlers is contrary to the typical BMI decrease observed during this developmental stage.

Conclusions:

  • While early infancy growth is relevant, rapid BMI increase in toddlers before age 3 is a stronger predictor of future cardiometabolic risk.
  • Targeted monitoring of BMI changes in toddlers is crucial for early identification of at-risk individuals.
  • Understanding these critical growth periods can inform preventative strategies against obesity and related diseases.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
988
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
711
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
130
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
110
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.8K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
91